Treats salt and water retention. ANDA 76698, held by Mylan. Metolazone.
As of Nov 16, 2026, ANDA 76698 (Metolazone), held by Mylan, was first approved by FDA on Dec 23, 2003, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Metolazone tablets are indicated for the treatment of salt and water retention including:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 2003 | Original application | Approved |
| Metolazone2.5MG · tablet;oral | Metolazone | Rx |
| Metolazone5MG · tablet;oral | Metolazone | Rx |
| Metolazone10MG · tablet;oral | Metolazone | Rx |
| Oct 19, 2004 | Supplement 1 | Approved | None posted |
| Oct 19, 2004 | Supplement 2Labeling | Approved | None posted |
| Oct 19, 2004 | Supplement 3 | Approved | None posted |
| Oct 19, 2004 | Supplement 4Labeling | Approved | None posted |
| Dec 23, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters